ASHM’s Taskforce on BBVs, Sexual Health and COVID-19 presents a lunchtime webinar - The Indigenous Health Response… https://t.co/bM2BFg81Rx
Clinical posts from members and guests of the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM) from various international medical and scientific conferences on HIV, AIDS, viral hepatitis, and sexual health.
Does Doxycycline Prophylaxis have a future?
The short answer from Jeffery Klausner (UCLA, CA) is; Yes.
Jeffery spoke about the two studies and looked at those results.
Antibiotic prevention is nothing new; Rheumatic fever, travellers (Malaria), Lyme Disease, or Travellers Diarrhoea.
With increasing Syphilis rates in MSM and the risk of facilitating HIV transmission, Doxycycline Prophylaxis could defiantly have a place.
As we already know, Doxycycline is a narrow spectrum antibiotic that is inexpensive.
Two RCT's were conducted; one study looked at daily 100mg Doxycycline for 30 men over 48 weeks (not behavioural intervention), on average most had 1mg/ml in samples with only a few having undetectable levels (?non adherence) which overall showed good levels.
- 73% reduction in Syphillis
- 70% reduction in other STI's (Chlamydia)
Study 2: On demand Doxycycline as PEP. RCT in HIV negative men on 200mg single dose up 24 hours after sex, maximum 72 hours post sex. NB: No more than six pills per week.
- 70-73% reduction in Syphilis and Chlamydia infections.
- No effect on Gonorrhoea.
- Noted increase in GI side effects, (nausea, GI pain and vomiting), nil adverse events.
Both studies showed great results, but more research needs to be done (Australia is part of a trial at the moment), and concerns around long term safety as well as ?Resistance (MRSA) were raised.
Overall a great presentation looking at the future of condomless prevention of STI's in a time where we have over 6000 MSM using condomless HIV prevention in NSW (EPIC, NSW)